<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Polyuria and diabetes insipidus of pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Polyuria and diabetes insipidus of pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Polyuria and diabetes insipidus of pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ravi I Thadhani, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sharon E Maynard, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 16, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H836273602"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Polyuria, a common complaint during normal pregnancy, is also one symptom of diabetes insipidus (DI). DI in pregnancy can be transient as a result of pregnancy-induced changes or represent worsening of preexisting central or nephrogenic DI. Recognition and management of DI during pregnancy is important because water restriction (as often occurs during labor and delivery) can result in serious neurologic consequences in both the mother and fetus.</p><p>This topic will discuss the clinical presentation, evaluation and diagnosis, and management of DI in pregnant patients. Related topics on polyuria and DI are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2372.html" rel="external">"Urine output in arginine vasopressin disorders (diabetes insipidus)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H2787686452"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Polyuria is defined as abnormal urine output that exceeds 3 L per 24 hours [<a href="#rid1">1</a>]. By contrast, changes in the lower urinary tract function during pregnancy result in increased frequency of urination without increased urine output.</p><p>DI is a disorder characterized by polyuria and polydipsia that results from loss of urine concentrating ability of the kidneys. DI in pregnancy may be due to central (eg, head trauma, pituitary adenoma) or nephrogenic (eg, gene mutations, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> toxicity) causes, or a result of increased metabolic clearance of antidiuretic hormone (also known as gestational DI  (<a class="graphic graphic_table graphicRef115436" href="/z/d/graphic/115436.html" rel="external">table 1</a>)) [<a href="#rid2">2</a>]. In all cases, the result is impaired renal water reabsorption, leading to production of a large volume of dilute urine. Urine osmolality and urine specific gravity are low. Both central and nephrogenic DI are discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p></p><p class="headingAnchor" id="H2078927624"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>DI affects approximately 4 per 100,000 pregnancies [<a href="#rid3">3</a>]. The types of DI are presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria", section on 'Causes of polyuria'</a>.)</p><p class="headingAnchor" id="H2458975617"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H2537842909"><span class="h2">Antidiuretic hormone and vasopressinase in pregnancy</span><span class="headingEndMark"> — </span>Antidiuretic hormone (ADH) increases renal water reabsorption and decreases urine output. This effect is mediated by activation of the V2 receptor in the renal collecting tubules, resulting in enhanced renal water reabsorption and the formation of concentrated urine. Most DI is caused by either inadequate ADH production (central DI) or renal resistance to ADH (nephrogenic DI). (See  <a class="medical medical_review" href="/z/d/html/2372.html" rel="external">"Urine output in arginine vasopressin disorders (diabetes insipidus)", section on 'Determinants of urine output'</a>.)</p><p>Between the eighth gestational week and midpregnancy, the metabolic clearance of ADH increases four- to sixfold because of an increase in vasopressinase (also known as oxytocinase), which is produced by the placenta. Vasopressinase activity peaks in the third trimester, remains high during labor and delivery, and then falls to undetectable levels two to four weeks postpartum. In most pregnant patients, plasma concentrations of ADH remain in the normal range, despite increased metabolic clearance, because of a compensatory increase in ADH production by the pituitary gland. As a result, most patients do not become polyuric.</p><p class="headingAnchor" id="H655507194"><span class="h2">Transient diabetes insipidus of pregnancy</span><span class="headingEndMark"> — </span>Transient DI of pregnancy is caused by an amplification of the normal pregnancy-related increase in vasopressinase levels or activity  (<a class="graphic graphic_table graphicRef115436" href="/z/d/graphic/115436.html" rel="external">table 1</a>).</p><p>Patients with preeclampsia; hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome; and acute fatty liver of pregnancy are at increased risk for transient DI of pregnancy. The mechanism in these cases is decreased degradation of vasopressinase due to hepatic dysfunction [<a href="#rid4">4,5</a>]. Patients with multiple gestations, because of a larger placental volume, have higher circulating levels of vasopressinase and thus are more likely to experience polyuria, particularly if there is coexistent hepatic dysfunction.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Oliguria'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3619.html" rel="external">"Acute fatty liver of pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H2126497210"><span class="h2">Pregnancy-induced exacerbation of preexisting diabetes insipidus</span><span class="headingEndMark"> — </span>Some pregnant patients have central or nephrogenic DI that was subclinical prior to pregnancy  (<a class="graphic graphic_table graphicRef115436" href="/z/d/graphic/115436.html" rel="external">table 1</a>) [<a href="#rid4">4,6,7</a>]. On careful questioning, they typically describe polyuria and polydipsia prior to pregnancy, with worsening of symptoms during pregnancy. Placental vasopressinase, which degrades circulating endogenously secreted ADH (vasopressin), results in overt ADH deficiency in patients with preexisting partial, largely asymptomatic, DI. In these cases, polyuria tends to recur with every pregnancy. True ADH- and desmopressin-resistant nephrogenic DI has been reported in a few patients [<a href="#rid6">6,8</a>]. The mechanism is uncertain, but spontaneous resolution occurs after delivery.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p></p><p class="headingAnchor" id="H2806185360"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The typical presenting features of DI are polydipsia and polyuria; these symptoms can be difficult to distinguish from urinary frequency of normal pregnancy [<a href="#rid2">2,4,6,9-14</a>]. The possibility of central, nephrogenic, or transient DI should be considered in patients with intense polydipsia and polyuria, especially in the third trimester  (<a class="graphic graphic_table graphicRef115436" href="/z/d/graphic/115436.html" rel="external">table 1</a>). Patients with DI generally report thirst and increased urinary output that are far greater than those normally seen in pregnant patients.</p><p>Hypernatremia does not occur unless access to water is restricted. In pregnant patients with DI who are undergoing cesarean birth or who are otherwise water restricted (eg, patients who are too ill to drink or with hyperemesis), severe hypernatremia can occur. The authors measure the serum sodium in any patient who reports polyuria and polydipsia, especially if access to water is limited. If serum sodium is &gt;140 mEq/L, a diagnostic work-up for DI should be performed [<a href="#rid2">2</a>].</p><p>New-onset DI can also present acutely in the postpartum period when postpartum hemorrhage leads to pituitary hypoperfusion and infarction (ie, Sheehan syndrome) [<a href="#rid6">6,15</a>]. (See  <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">"Causes of hypopituitarism", section on 'Pituitary infarction (Sheehan syndrome)'</a>.)</p><p class="headingAnchor" id="H3375559083"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>A diagnostic evaluation for DI in pregnancy should be performed in patients with polyuria (urine output &gt;3 L/day) or polydipsia, particularly if hypernatremia is present. A 24-hour urine collection should be done to confirm true polyuria, although collection can be cumbersome and is often incomplete (see  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a>). DI of pregnancy (any cause) is diagnosed in pregnant patients with polyuria and polydipsia, an increased serum sodium (&gt;140 mEq/L), and an inappropriately dilute urine (urine osmolality &lt;300 mOsm/kg) [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H3702263886"><span class="h2">Water restriction test</span><span class="headingEndMark"> — </span>The standard confirmatory test for the diagnosis of DI is the water restriction test with assessment of urinary response to <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a>. Desmopressin is not degraded by vasopressinase, so it is effective in increasing the urine osmolality and decreasing polyuria in patients with transient DI of pregnancy.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are already hypernatremic (ie, serum sodium &gt;143 mEq/L), the response to <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> (10 mcg intranasally or 4 mcg subcutaneously or intravenously) may be assessed without the need for further water restriction. (See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria", section on 'Patients with hypernatremia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have polyuria and polydipsia but normal serum sodium, water restriction is generally necessary. Water restriction must be completed in a hospital setting with close monitoring, as dehydration can result in uteroplacental insufficiency [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria", section on 'Patients with a normal serum sodium'</a>.)</p><p></p><p>Copeptin, a stable protein cosecreted with ADH, is emerging as a potential biomarker to distinguish central from nephrogenic DI in patients with polyuria/polydipsia. There are no data on use of this assay in pregnant patients for the evaluation of polyuria, though it has been studied as a predictor of preeclampsia [<a href="#rid2">2,17</a>].</p><p class="headingAnchor" id="H3983172254"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>When evaluating pregnant patients for possible DI, the clinician should consider and exclude the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary polydipsia</strong> – Primary polydipsia, or psychogenic polydipsia, is a disorder of increased water intake, leading to increased urine output. In patients with primary polydipsia, limiting water intake results in a rapid reduction in polyuria and an increase in urine osmolality. Primary polydipsia does not cause hypernatremia. (See  <a class="medical medical_review" href="/z/d/html/2374.html" rel="external">"Causes of hypotonic hyponatremia in adults", section on 'Primary polydipsia due to psychosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinary frequency without polyuria</strong> – Urinary frequency is almost universal in pregnancy but does not usually reflect a pathologic increase in urine volume. Urinary frequency is distinguished from true polyuria by urine output less than 3 L/day in a 24-hour urine collection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypernatremia due to inadequate water intake</strong> – Hypernatremia (without polyuria) can develop in any individual with inadequate free water intake, such as a patient with hyperemesis gravidarum. This is easily distinguished from DI by the presence of an appropriately concentrated urine (urine osmolality &gt;300 mOsm/kg, and usually much higher). In these cases, polyuria is absent and patients are often oliguric. Loop diuretics decrease urinary concentrating ability and must be held for this to be reliable.</p><p></p><p class="headingAnchor" id="H454288377"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Management of DI in pregnancy includes treatment of hypernatremia (if present) and then treatment of the underlying cause.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypernatremia</strong> – Hypernatremia in pregnancy, regardless of etiology, should be corrected by replacing free water. This may be done either orally or intravenously (ie, as 5% dextrose in water). Acute hypernatremia can be corrected rapidly. By contrast, chronic hypernatremia should be corrected slowly to reduce the risk of cerebral edema, a complication that has been reported primarily in infants. (See  <a class="medical medical_review" href="/z/d/html/2339.html" rel="external">"Treatment of hypernatremia in adults", section on 'Choosing a rate of correction'</a>.)</p><p></p><p class="bulletIndent1">In addition to correcting the free water deficit, ongoing free water losses from urine output and insensible losses should be replaced. An indwelling bladder catheter may be needed for accurate measurement of urine output if the patient is unable to cooperate with urine output measurement. (See  <a class="medical medical_review" href="/z/d/html/2339.html" rel="external">"Treatment of hypernatremia in adults", section on 'Approach to therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transient or central DI </strong>– Polyuria due to transient DI of pregnancy or central DI in pregnancy can be effectively treated with <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP), a vasopressin analog, which is resistant to degradation by vasopressinase [<a href="#rid4">4,6,18</a>]. For patients with intact thirst and access to water, a reasonable starting dose is 10 mcg intranasally or 0.05 mg orally, either at bedtime or twice daily. The dose should be titrated to achieve relief of polyuria and a serum sodium of 133 to 140 mEq/L, targeting the mild physiologic hyponatremia of pregnancy [<a href="#rid2">2,11</a>]. Doses equal to or slightly higher than those used to treat central DI in nonpregnant patients are typically required [<a href="#rid2">2</a>]. The dose and dosing interval are adjusted to allow mild polyuria between doses and thus avoid severe hyponatremia. No adverse maternal or fetal effects from desmopressin use during pregnancy have been reported, although trial data are lacking [<a href="#rid19">19</a>]. Although DDAVP has a structure similar to <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a>, use of intranasal DDAVP has not been associated with induction of labor [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/2313.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Treatment", section on 'Desmopressin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrogenic DI</strong> – Management of polyuria in pregnant patients with nephrogenic DI in pregnancy can be difficult. Treatment strategies in nonpregnant patients include thiazide diuretics and nonsteroidal anti-inflammatory agents, but these agents are generally avoided in pregnancy. Similarly, a low-protein, low-sodium diet may decrease polyuria, but its safety in pregnancy has not been studied. Patients should be encouraged to drink to thirst, with continuous access to water, to avoid hypernatremia. (See  <a class="medical medical_review" href="/z/d/html/2382.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H4094105176"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Hypernatremia can occur if water intake is restricted, as it often is in the peripartum period [<a href="#rid11">11,13,20</a>]. Pregnant patients with DI in whom oral intake must be restricted (eg, those undergoing cesarean birth) should be managed with hypotonic intravenous fluids at a rate to match their urine output and frequent monitoring of serum sodium concentration.</p><p>While the overall risk of obstetric complications is similar for patients with and without DI of pregnancy, limited data suggest an association between transient DI of pregnancy and preeclampsia [<a href="#rid2">2,14,21,22</a>]. Oligohydramnios has also been reported [<a href="#rid20">20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6777.html" rel="external">"Oligohydramnios: Etiology, diagnosis, and management in singleton gestations"</a>.)</p><p></p><p class="headingAnchor" id="H3802559298"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Gestational DI caused by increased vasopressinase activity resolves postpartum and does not usually recur in subsequent pregnancies.</p><p class="headingAnchor" id="H56762944"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Polyuria is defined as urine output that exceeds 3 L per 24 hours. Diabetes insipidus (DI) is a disorder characterized by polyuria and polydipsia that results from loss of urine concentrating ability of the kidneys. DI can result from central causes, nephrogenic causes, or be transiently related to pregnancy. DI occurs in approximately 4 per 100,000 pregnancies. (See <a class="local">'Definition'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antidiuretic hormone (ADH) increases renal water reabsorption, thereby concentrating the urine. Between the eighth week and midpregnancy, the metabolic clearance of ADH increases four- to sixfold because of an increase in vasopressinase, which is produced by the placenta. (See <a class="local">'Antidiuretic hormone and vasopressinase in pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transient DI of pregnancy is caused by an amplification of the normal pregnancy-related increase in vasopressinase levels or activity. Patients with preeclampsia; hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome; and acute fatty liver of pregnancy are at increased risk for transient DI of pregnancy, presumably through decreased degradation of vasopressinase in the setting of hepatic dysfunction. (See <a class="local">'Transient diabetes insipidus of pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some pregnant patients with signs and symptoms of DI have central or nephrogenic DI that was subclinical prior to pregnancy. (See <a class="local">'Pregnancy-induced exacerbation of preexisting diabetes insipidus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The polydipsia and polyuria associated with DI in pregnancy can be difficult to distinguish from normal pregnancy. The possibility of central, nephrogenic, or transient DI should be considered in patients with intense polydipsia and polyuria (ie, more severe than typically seen in pregnancy) and in patients whose symptoms develop in the third trimester  (<a class="graphic graphic_table graphicRef115436" href="/z/d/graphic/115436.html" rel="external">table 1</a>). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnostic evaluation of DI in pregnancy begins with a 24-hour urine collection. Patients with polyuria, defined as a urine output that exceeds 3 L per 24 hours, require a <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> challenge with or without supervised water restriction. Some patients can delay evaluation until they are postpartum. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of DI is confirmed in a patient with polyuria by an increased serum sodium (&gt;140 mEq/L) and an inappropriately dilute urine (urine osmolality &lt;300 mOsm/kg). (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Water restriction test'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When evaluating pregnant patients for possible DI, the clinician should consider and exclude the following: primary polydipsia, urinary frequency (without polyuria), and hypernatremia due to inadequate water intake. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transient DI of pregnancy and central DI in pregnancy can be effectively treated with <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP), a vasopressin analog that is resistant to degradation by vasopressinase. For patients with intact thirst and access to water, a reasonable starting dose is 10 mcg intranasally or 0.05 mg orally, either at bedtime or twice daily. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypernatremia, which can occur if water intake is restricted, can result in serious neurologic consequences in both the mother and fetus. Hypernatremia should be treated with intravenous hypotonic fluid. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While the overall risk of obstetric complications is similar for patients with and without DI of pregnancy, limited data suggest an association between transient DI of pregnancy and preeclampsia. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transient DI of pregnancy resolves postpartum and does not usually recur in subsequent pregnancies. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am 2001; 30:671.</a></li><li><a class="nounderline abstract_t">Ananthakrishnan S. Diabetes insipidus during pregnancy. Best Pract Res Clin Endocrinol Metab 2016; 30:305.</a></li><li><a class="nounderline abstract_t">Hime MC, Richardson JA. Diabetes insipidus and pregnancy. Case report, incidence and review of literature. Obstet Gynecol Surv 1978; 33:375.</a></li><li><a class="nounderline abstract_t">Durr JA, Lindheimer MD. Diagnosis and management of diabetes insipidus during pregnancy. Endocr Pract 1996; 2:353.</a></li><li><a class="nounderline abstract_t">Kennedy S, Hall PM, Seymour AE, Hague WM. Transient diabetes insipidus and acute fatty liver of pregnancy. Br J Obstet Gynaecol 1994; 101:387.</a></li><li><a class="nounderline abstract_t">Dürr JA. Diabetes insipidus in pregnancy. Am J Kidney Dis 1987; 9:276.</a></li><li><a class="nounderline abstract_t">Iwasaki Y, Oiso Y, Kondo K, et al. Aggravation of subclinical diabetes insipidus during pregnancy. N Engl J Med 1991; 324:522.</a></li><li><a class="nounderline abstract_t">Ford SM Jr, Lumpkin HL 3rd. Transient vasopressin-resistant diabetes insipidus of pregnancy. Obstet Gynecol 1986; 68:726.</a></li><li><a class="nounderline abstract_t">Lindheimer MD, Barron WM, Davison JM. Osmotic and volume control of vasopressin release in pregnancy. Am J Kidney Dis 1991; 17:105.</a></li><li><a class="nounderline abstract_t">Durr JA, Hoggard JG, Hunt JM, Schrier RW. Diabetes insipidus in pregnancy associated with abnormally high circulating vasopressinase activity. N Engl J Med 1987; 316:1070.</a></li><li><a class="nounderline abstract_t">Brewster UC, Hayslett JP. Diabetes insipidus in the third trimester of pregnancy. Obstet Gynecol 2005; 105:1173.</a></li><li><a class="nounderline abstract_t">Aleksandrov N, Audibert F, Bedard MJ, et al. Gestational diabetes insipidus: a review of an underdiagnosed condition. J Obstet Gynaecol Can 2010; 32:225.</a></li><li><a class="nounderline abstract_t">Sherer DM, Cutler J, Santoso P, et al. Severe hypernatremia after cesarean delivery secondary to transient diabetes insipidus of pregnancy. Obstet Gynecol 2003; 102:1166.</a></li><li><a class="nounderline abstract_t">Katz VL, Bowes WA Jr. Transient diabetes insipidus and preeclampsia. South Med J 1987; 80:524.</a></li><li><a class="nounderline abstract_t">Matsuzaki S, Endo M, Ueda Y, et al. A case of acute Sheehan's syndrome and literature review: a rare but life-threatening complication of postpartum hemorrhage. BMC Pregnancy Childbirth 2017; 17:188.</a></li><li><a class="nounderline abstract_t">Lindheimer MD. Polyuria and pregnancy: its cause, its danger. Obstet Gynecol 2005; 105:1171.</a></li><li><a class="nounderline abstract_t">Yeung EH, Liu A, Mills JL, et al. Increased levels of copeptin before clinical diagnosis of preeclampsia. Hypertension 2014; 64:1362.</a></li><li><a class="nounderline abstract_t">Davison JM, Sheills EA, Philips PR, et al. Metabolic clearance of vasopressin and an analogue resistant to vasopressinase in human pregnancy. Am J Physiol 1993; 264:F348.</a></li><li><a class="nounderline abstract_t">Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998; 53:450.</a></li><li><a class="nounderline abstract_t">Hanson RS, Powrie RO, Larson L. Diabetes insipidus in pregnancy: a treatable cause of oligohydramnios. Obstet Gynecol 1997; 89:816.</a></li><li><a class="nounderline abstract_t">Hadi HA, Mashini IS, Devoe LD. Diabetes insipidus during pregnancy complicated by preeclampsia. A case report. J Reprod Med 1985; 30:206.</a></li><li><a class="nounderline abstract_t">Mor A, Fuchs Y, Zafra K, et al. Acute presentation of gestational diabetes insipidus with pre-eclampsia complicated by cerebral vasoconstriction: a case report and review of the published work. J Obstet Gynaecol Res 2015; 41:1269.</a></li></ol></div><div id="topicVersionRevision">Topic 115441 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11571936" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antidiuretic hormone. Normal and disordered function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27156766" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diabetes insipidus during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/652196" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diabetes insipidus and pregnancy. Case report, incidence and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15251517" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis and management of diabetes insipidus during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018608" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Transient diabetes insipidus and acute fatty liver of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3554998" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diabetes insipidus in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992305" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Aggravation of subclinical diabetes insipidus during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3763091" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Transient vasopressin-resistant diabetes insipidus of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992649" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Osmotic and volume control of vasopressin release in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3561459" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diabetes insipidus in pregnancy associated with abnormally high circulating vasopressinase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863571" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diabetes insipidus in the third trimester of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20500966" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gestational diabetes insipidus: a review of an underdiagnosed condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14607044" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Severe hypernatremia after cesarean delivery secondary to transient diabetes insipidus of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3563589" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transient diabetes insipidus and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28615049" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A case of acute Sheehan's syndrome and literature review: a rare but life-threatening complication of postpartum hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863570" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Polyuria and pregnancy: its cause, its danger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25225209" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Increased levels of copeptin before clinical diagnosis of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8447444" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Metabolic clearance of vasopressin and an analogue resistant to vasopressinase in human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9662731" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : DDAVP use during pregnancy: an analysis of its safety for mother and child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166332" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diabetes insipidus in pregnancy: a treatable cause of oligohydramnios.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3999072" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Diabetes insipidus during pregnancy complicated by preeclampsia. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832854" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Acute presentation of gestational diabetes insipidus with pre-eclampsia complicated by cerebral vasoconstriction: a case report and review of the published work.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
